NCT02690883View on ClinicalTrials.gov

Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy

PHASE4CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

April 8, 2016

Primary Completion Date

December 13, 2019

Study Completion Date

December 30, 2019

Conditions
Diabetic Nephropathies
Interventions
DRUG

Exenatide

Exenatide (Astrazeneca ) 5 μg(initial dose)/10ug(maintenance dose) Subcutaneous injection Bid

DRUG

Lispro

Lispro (Eli Lilly), the dosage is initiated according to the previous treatment plan and weight of the patients, distribute the dosage to 1:1:1 before 3 meals, titration following PPG \<10.0mmol/L.

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER

NCT02690883 - Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy | Biotech Hunter | Biotech Hunter